Reviewer’s report

Title: Reduced Frequency of Intravitreal Methotrexate Lowers the Risk of Keratopathy in Vitreoretinal Lymphoma Patients

Version: 0 Date: 29 Feb 2020

Reviewer: Yo-Chen Chang

Reviewer's report:

Page 1 (title page): Author's first and last names, some are separated, some are linked together, please correct

Page 2, line 12: I suggest that "divided" to be replaced by "assigned"

Page 4, line 4: "intraocular lymphoma is also known as", the "intraocular" should be "Intraocular".

Page 4, line 15: "intraocular lymphoma is even responsive to", the "intraocular" should be "Intraocular". And the "even" might be replaced by "initially".

Page 4, line 21: The "ophthalmologist" should be "ophthalmologists"

Page 5, line 2-5: Please cite references for "The most widely used intravitreal methotrexate treatment regimen consists of three phases: induction, consolidation and maintenance. In detail, it is composed of injection with a dose of 400μg/0.1 ml twice a week for the first four weeks, weekly for the followed eight weeks, and then monthly for the last nine months."

Page 5, line 2-5: "intraocular lymphoma prognosis" might be replaced by "the prognosis of intraocular lymphoma".

Page 5, method part, line 4: "Patients with systemic lymphoma were excluded". Do you mean "Patients with pre-existing systemic lymphoma were excluded"?

Page 6, line 4: "diagnostic 25Gpars plana vitrectomy (PPV) which were performed by one skilled surgeon." Please add the initials of the surgeon.

Page 6, treatment part, line 4: "6 patients (8 eyes) treated with induction-maintenance regimen", the "6" might be replaced by "Six"

Page 6, treatment part, line 10-11"Complete Remission was described as the absence of malignant cells in vitreous, retina or optic nerve head." How do the authors confirm the complete remission? By repeated PPV, etc?

Page 8, line 3-4: "However, 38% of patients diagnosed with intraocular lymphoma had no ocular symptoms." Actually, from literature review and clinical experience, most patients have painless decrease in vision or floaters. Please explain why so many patients in your series had no symptoms?
Page 8, line 18-20: "The undiluted vitreous specimens contained $121 \times 10^6$ cells/mL compared with $17 \times 10^6$ cells/mL in diluted samples ($P=0.009$)." Are the two data represented the mean of the 33 eyes? If they are, please add "mean" or "average" and give the data as Mean±STD.

Page 9, line 11-12: "12 eyes did not complete the entire treatment but achieved ocular clinical remission." Please use "Twelve" instead of "12". Please mention the number in both group separately.

Page 10, line 11-12: "However, 9 patients suffered recurrence of the CNS lymphoma, 6 patients in Group A and 3 in Group B ($P=0.666$)." The sentence is strange, please rewrite.

Page 12, last paragraph, line 3-4: "The lower incidence of keratopathy in Group B is probably due to the shorter injection duration of high frequency." I remember the protocol in Group B is longer injection duration of low frequency, am I right?

Page 13, The paragraph: "Rituximab is a mouse-human chimeric monoclonal antibody against the CD20 antigen on the membrane of B cells(24, 30, 33). Some nonrandomized studies showed that intravitreal rituximab monotherapy might be effective for intraocular lymphoma(28, 33, 34). Long-term and large sample studies of the rituximab treatment are still absent. More evidence is needed to support Rituximab treatment as a first-line treatment." Since the authors did not use Rituximab, I suggest delete the paragraph.

Generally speaking, the content of the manuscript is interesting, however, major revision and professional language editing by native English speaker are necessary.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Not suitable for publication unless extensively edited

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

No

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal